Navigation Links
Cornerstone Therapeutics Reports Year Ended December 31, 2008 Financial Results
Date:3/26/2009

o a $2.7 million increase in labor, benefits and related employee expenses due to the growth of the Company and $1.4 million in merger-related legal and accounting expenses that were not capitalized.

Research and development expenses were $3.8 million in 2008, compared to $948,000 in 2007, an increase of approximately $2.9 million, or 305%. Research and development expenses in 2008 included additional expenses related to pipeline development, as well as the write-off of $1.9 million of in-process research and development related to an alpha-7 product candidate that was acquired from Critical Therapeutics.

For the 12 months ended December 31, 2008, the Company had operating income of $10.6 million, or 16.4% of net revenues, compared with operating income of $2.4 million or 8.7% of net revenues, for the same period in 2007, an increase of approximately 341%. The Company's 2008 net income and diluted earnings per share were $9.0 million and $1.14, respectively.

"We are extremely pleased with the successful completion of our merger, with net product sales more than doubling from 2007 and with the continued growth in operating income and cash flow from operations that we experienced in 2008," said Craig A. Collard, Cornerstone's President and Chief Executive Officer. "We remain focused on driving profitable growth by expanding our sales and marketing team within the respiratory market to further drive our current market penetration. In addition, we believe the advancement of our existing product pipeline, combined with additional in-licensing and product acquisition opportunities will support our revenue and operating profit in the future."

As of December 31, 2008, the Company had $9.3 million in cash and cash equivalents and borrowing availability of $3.9 million under a line of credit with Paragon Commercial Bank.

2009 Outlook

For the full year, Corners
'/>"/>

SOURCE Cornerstone Therapeutics Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related biology technology :

1. Cornerstone Therapeutics to Host Quarter and Year Ended December 31, 2008 Conference Call
2. Cornerstone Therapeutics Provides Update on Integration Activities and Issues 2008 Revenue Guidance
3. Cell Therapeutics, Inc. Reports Outcome of Special Meeting of Shareholders
4. Cell Therapeutics, Inc. Special Meeting in Lieu of Annual Meeting of Shareholders Scheduled for Tuesday, March 24, 2009
5. Cell Therapeutics Announces Filing of Form 10-K
6. Horizon Therapeutics Selected to Present at InsideVentures Debut Investor Conference March 25-26, Santa Barbara, California
7. Oxygen Biotherapeutics, Inc. Expands Board of Directors
8. Micromet Adds Sir Walter Bodmer and Bernard Fox to Its Advisory Panel for BiTE Antibody Therapeutics
9. Cell Therapeutics Presents Corporate Highlights at Invest Northwest Conference
10. Nile Therapeutics Announces Information in Compliance With NASDAQ Marketplace Rule 4350 and Reiterates 2009 Objectives
11. Medarex to Present at the Needham Cancer Therapeutics Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/18/2014)... 2014) -- A new therapy developed by researchers ... College of Medicine and Columbia University Medical Center ... interventional cardiovascular disease treatment. , The researchers ... molecular therapy could selectively inhibit blood vessel re-narrowing ... procedure using a balloon catheter to open narrowed ...
(Date:8/18/2014)... 18, 2014   Sterne, Kessler, Goldstein & Fox ... Washington, DC , announced today that it ... (IPR) with the U.S. Patent and Trademark Office ... BioReference Laboratories, Inc. (Nasdaq: BRLI).  These IPR petitions aim ... Myriad Genetics, Inc. These patents have been asserted against ...
(Date:8/18/2014)... According to a new ... Science Reagents Market(Products- PCR Reagent Kits, Cell and ... Reagents and Others; End Users- Commercial and Contract ... Forensic Laboratories)- Global Industry Analysis, Size, Share, Growth, ... life science reagents market was valued at USD ...
(Date:8/18/2014)... 2014 Dyadic International, Inc. ("Dyadic") (OTCQX: ... proprietary technologies are used to develop, manufacture and ... bio-based chemical, biopharmaceutical and industrial enzyme industries, announced ... on Form 10 with the U.S. Securities and ... http://photos.prnewswire.com/prnh/20110621/CL06708LOGO The Form ...
Breaking Biology Technology:Selective therapy may improve artery repair after interventional cardiovascular procedures 2Selective therapy may improve artery repair after interventional cardiovascular procedures 3Sterne Kessler Files 11 IPR Petitions On Behalf Of GeneDx, Inc., Subsidiary Of BioReference Laboratories, Inc. 2Sterne Kessler Files 11 IPR Petitions On Behalf Of GeneDx, Inc., Subsidiary Of BioReference Laboratories, Inc. 3Global Life Science Reagents Market Expected to Reach USD 25.7 Billion in 2019: Transparency Market Research 2Global Life Science Reagents Market Expected to Reach USD 25.7 Billion in 2019: Transparency Market Research 3Global Life Science Reagents Market Expected to Reach USD 25.7 Billion in 2019: Transparency Market Research 4Global Life Science Reagents Market Expected to Reach USD 25.7 Billion in 2019: Transparency Market Research 5Dyadic International Files Form 10 Registration Statement 2Dyadic International Files Form 10 Registration Statement 3Dyadic International Files Form 10 Registration Statement 4
... ... in Chicago. , ... Chicago (Vocus) April 22, 2010 -- Therapeutic Proteins Inc. (TPI) today announced ... constructed to meet U.S. Food and Drug Administration (FDA) requirements. The Chicago facility is ...
... a tactile-based probe technique, provides a three-dimensional nanoscale image ... the material,s surface. The core of AFM imaging workhorse ... as it encounters undulations across a surface. Due ... cantilevers can deform or even tear apart living ...
... ... Shear Processing Leader Applies For Microfluidics Reaction Technology™ (MRT) Patent in Japan ... Newton, ... that, along with its exclusive Japanese distributor, POWREX Corporation, it has introduced Microfluidics ...
Cached Biology Technology:Therapeutic Proteins Inc. Completes First Independent, Dedicated Biosimilars Manufacturing Facility in U.S. 2Therapeutic Proteins Inc. Completes First Independent, Dedicated Biosimilars Manufacturing Facility in U.S. 3Therapeutic Proteins Inc. Completes First Independent, Dedicated Biosimilars Manufacturing Facility in U.S. 4A little less force: Making atomic force microscopy work for cells 2Microfluidics and POWREX Launch Revolutionary Continuous Pharmaceutical Manufacturing Technology in Japan 2Microfluidics and POWREX Launch Revolutionary Continuous Pharmaceutical Manufacturing Technology in Japan 3
(Date:8/19/2014)... study that analyzed concentrations of African dust transported ... winter and spring. These research findings offer new ... quality impacts of African dust, including the climate ... occur from increased African dust emissions in the ... (UM) Rosenstiel School of Marine and Atmospheric Science ...
(Date:8/19/2014)... available in French . ... and RISKS of physical activity in children,Today the Canadian ... promotion of childhood physical activity and published their position ... and Metabolism ( APNM ). This position ... area of risk of physical activity for children and ...
(Date:8/19/2014)... Florida , August 19, 2014 ... Options / Digital Wallet Choices as latest developments, ad ... eBay Inc. (NASDAQ: EBAY ), Amazon.com Inc. ... AAPL ), Google Inc. (NASDAQ: GOOG ... Inc., (OTCQB: NXTD) a biometric authentication company focused on ...
Breaking Biology News(10 mins):Study of African dust transport to South America reveals air quality impacts 2Taking a stand: Balancing the BENEFITS and RISKS of physical activity in children 2Taking a stand: Balancing the BENEFITS and RISKS of physical activity in children 3Digital Wallet Choices; PayPal, Google Wallet, Apple Passbook - and Now Wocket Smart Wallet : Who Addresses Issues of Security? 2Digital Wallet Choices; PayPal, Google Wallet, Apple Passbook - and Now Wocket Smart Wallet : Who Addresses Issues of Security? 3Digital Wallet Choices; PayPal, Google Wallet, Apple Passbook - and Now Wocket Smart Wallet : Who Addresses Issues of Security? 4Digital Wallet Choices; PayPal, Google Wallet, Apple Passbook - and Now Wocket Smart Wallet : Who Addresses Issues of Security? 5Digital Wallet Choices; PayPal, Google Wallet, Apple Passbook - and Now Wocket Smart Wallet : Who Addresses Issues of Security? 6Digital Wallet Choices; PayPal, Google Wallet, Apple Passbook - and Now Wocket Smart Wallet : Who Addresses Issues of Security? 7
... Pennsylvania studying oocytes in mice, the immature egg cells ... in microRNA, or miRNA, activity that may be the ... blastomeres of the embryo. MicroRNAs are a member of ... of the biological world. MicroRNAs imperfectly pair with ...
... , HASBROUCK HEIGHTS, N.J. , Feb. 3 Zymes ... Omega-3 enhanced water, will be sampled at the NFL Alumni,s Super Bowl ... Florida .  This presence of OmegaChill at Super Bowl XLIV ... term heart and mind health will serve as keynotes to Zymes LLC,s ...
... investigate whether long-term weekly iron and folic acid supplementation ... malaria. The information provided by the study, based in ... health services and develop effective preventative programmes for anaemia ... during or shortly after adolescence may enter pregnancy with ...
Cached Biology News:Penn biologists determine microRNA activity is suppressed in mouse ovum 2Zymes LLC's Omega-3 Enhanced Water OmegaChill to be Distributed at NFL Alumni Super Bowl XLIV Weekend Events on February 5-7th, 2010 2LSTM begins £0.5 million malaria study in Burkina Faso 2
... The Genome Sequencer 20 System revolutionizes DNA ... parallel fashion. The Genome Sequencer 20 ... Reagents and consumables for library construction, ... mapping and de novo assembly ...
... is critical to the maintenance of ... proteins as important and diverse as ... shock and stress response, antigen presentation, ... ion channels, cell cycle regulation, transcription, ...
Compound(s) tested through a broad panel of 38 ligand binding and enzyme assays targeting the Central Nervous System. Used to determine selectivity and potential CV/Renal liabilities of compounds....
... demonstrated that oxidative stress is involved in ... stress is the condition in which an ... exist leading to the damage of a ... stress is through several antioxidant systems4 that ...
Biology Products: